Please join us for a panel discussion of the key areas for consideration based on the recent changes in the revenue recognition rules and how those changes could impact deal structures. Our panel of experts will highlight the areas of interest for pharmaceutical and medical device companies and provide practical guidance for dealing with these changes in partnering and other arrangements, including:

• Recognizing near-term revenue under agreements with long-term commitments
• Impact on structure of collaboration agreements
• Considerations for distribution arrangements